Objective:To evaluate the efficacy and safety of toripalimab in the comprehensive treatment of bladder urothelial carcinoma(UBC)and atypical bladder tumor(ABT)in real-world settings.Methods:Data from 46 patients with bladder tumors(32 with UBC and 14 with ABT)who underwent surgery combined with toripalimab treatment were included for analysis of occurrence rates of treatment-related adverse reactions and efficacy during the treatment period.Results:For the 32 patients with UBC and 14 patients with ABT,the overall recurrence rate was 15.2％after the comprehensive treatment with toripalimab.Common adverse reactions ob-served in the 46 patients included pruritus(17.4％),thyroid dysfunction(15.2％),and decreased appetite(10.9％).There were 14 events of grade 3-4 adverse reactions,accounting for 36.8％of the total adverse events.Conclusion:Toripalimab demonstrates signifi-cant efficacy and overall manageable safety in the comprehensive treatment of UBC and ABT.However,vigilance is necessary for ad-verse reactions.
关键词
特瑞普利单抗/综合治疗/膀胱尿路上皮癌/特殊类型膀胱肿瘤/不良反应
Key words
toripalimab/comprehensive treatment/bladder urothelial carcinoma/special types of bladder tumor/adverse reaction
维普
万方数据